ALNYLAM PHARMACEUTICALS, INC. Prepaid Expense and Other Assets, Current
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Prepaid Expense and Other Assets, Current of $302.18 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-07-30
- 2026-06-30: Prepaid Expense and Other Assets, Current $302.18M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $281.89M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $188.04M.
- 2025-06-30: Prepaid Expense and Other Assets, Current $147.31M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $302.18M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $281.89M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $188.04M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $147.31M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $152.42M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $116.96M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $145.35M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $154.75M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $201.96M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $126.38M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $157.96M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $145.45M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $119.03M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $132.92M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $125.52M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $129.78M 10-Q · filed 2022-07-28 | |
| 2022-03-31 | $115.06M 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $88.08M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $108.53M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $94.14M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $75.98M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $62.77M 10-K · filed 2022-02-10 | |
| 2020-09-30 | $74.77M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $88.35M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $98.70M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $80.34M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $73.54M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $65.62M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $81.67M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $73.71M 10-K · filed 2020-02-13 | |
| 2018-09-30 | $90.84M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $51.93M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $66.67M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $40.12M 10-K · filed 2019-02-14 | |
| 2017-09-30 | $30.43M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $22.03M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $18.13M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $21.74M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $19.28M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $22.15M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $27.63M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $16.56M 10-K · filed 2017-02-15 | |
| 2015-09-30 | $17.45M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $15.12M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $13.21M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $9.74M 10-K · filed 2016-02-12 | |
| 2014-09-30 | $10.70M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $10.27M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $8.41M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $3.91M 10-K · filed 2015-02-13 | |
| 2013-09-30 | $4.78M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $4.21M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $3.54M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $2.64M 10-K · filed 2014-02-20 | $2.54M 10-K · filed 2013-02-19 |
| 2012-09-30 | $5.68M 10-Q · filed 2012-11-05 | |
| 2012-06-30 | $6.93M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $7.25M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $4.16M 10-K · filed 2013-02-19 | |
| 2011-09-30 | $4.91M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $5.08M 10-Q · filed 2011-08-03 | |
| 2010-12-31 | $6.89M 10-K · filed 2012-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |